Salus IRB board members are qualified, knowledgeable experts, many with years of experience as investigators conducting clinical trials. Salus boards are appropriately comprised of both genders and are racially and culturally diverse, satisfying the requirements of 21 CFR 56.107 and 45 CFR 46.107.
Salus boards include physicians, pharmacists, doctors of pharmacy, ethicists attorneys, toxicologists, radiation safety officers, and nurses (including pediatric and oncology), as well as lay community members who do not have scientific or medical backgrounds. Salus board members have industry experience in drug safety, drug development, regulatory and medical affairs, protocol development and monitoring, research science, patient/research participant advocacy, and working with vulnerable populations. The boards may utilize a special consultant to assist in the review of a protocol requiring additional expertise to supplement that of the board.
The boards review phase I-IV research, post-marketing surveillance, drug, device, social/behavioral, first-in-man, adaptive protocol designs, phase I oncology, companion diagnostics, human factors and usability studies, investigator-initiated research, innovative research, and outcomes research in a variety of therapeutic areas in the pharmaceutical, biotech, and medical device industries including, but not limited to: